During the past decade, Puget Sound Blood Center conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 8 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Puget Sound Blood Center" #1 sponsor was "Baxalta now part of Shire" with 6 trials, followed by "Bloodworks" with 2 trials sponsored, "Bioverativ Therapeutics Inc." with 1 trials sponsored, "Cellphire Therapeutics, Inc." with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Puget Sound Blood Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator and "Duke University" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Puget Sound Blood Center" are "Hemophilia A" (7 trials), "Hemophilia B" (4 trials), "Healthy" (2 trials), "Blood Coagulation Disorder" (1 trials) and "Blood Coagulation Disorders, Inherited" (1 trials). Many other conditions were trialed in "Puget Sound Blood Center" in a lesser frequency.

Most popular intervention types in "Puget Sound Blood Center" are "Drug" (11 trials), "Biological" (7 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Antihemophilic factor, recombinant, manufactured protein-free" (2 trials), "Placebo" (2 trials), "ADVATE (Antihemophilic Factor [Recombinant])" (1 trials), "Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method" (1 trials) and "AskBio009" (1 trials). Other intervention names were less common.

The vast majority of trials in "Puget Sound Blood Center" are 10 trials for "All" genders, 8 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Puget Sound Blood Center". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Puget Sound Blood Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Puget Sound Blood Center, 4 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Puget Sound Blood Center has several departments that took part in Clinical trials: "Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia" - 7 trials